Media library
Multimedia content
Our videos: the Phase 2 clinical trial, patient stories, and explanations of Targeted Active Therapy for myasthenia gravis.
Stories & testimonies
The journey of Dr. Stéphane Huberty, founder and a patient himself.
The founder's story, short version.
Carlos, a patient, shares his experience.
Daily life and the challenges of people living with MG.
Uto, a nine-month-old Golden Retriever, was the first dog treated with CV-MG01.
After Uto, Teddy the Labradoodle received CV-MG01 and is on the road to remission.
Carlos, a patient, shares his experience.
The project and the Phase 2 trial
The Phase 2 clinical trial, in brief.
Where the clinical trials stand and why Phase 2 is decisive.
The science and the discovery
Discover how Myasthenia Gravis (MG) affects the neuromuscular junction and how CuraVac's Targeted Active Therapy for MG precisely targets the antibody responsible for the disease.
The discovery of complementary peptides by Prof. J. Edwin Blalock.
From scientific discovery to therapeutic development.
The mechanism of TAT, explained simply.
Dr. Huberty administers the treatment to himself, in 2010.
All our videos
Find all of our content on our YouTube channel.